Market Overview:
The global age-related macular degeneration (AMD) treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing prevalence of AMD, rising geriatric population, and technological advancements in the field of ophthalmology. The global age-related macular degeneration (AMD) treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into Lucentis, Eylea, Avastin and other drugs. Lucentis held a dominant share in 2017 owing to its high efficacy and safety profile as compared to other drugs available in the market for treating AMD. On the basis of application, hospital held a major share in 2017 due to increasing number of hospital admissions for AMD patients across regions. However; clinics are expected to witness highest growth during forecast period due to growing demand for outpatient care services for AMD patients globally. Geographically; North America accounted for largest share in 2017 followed by Europe owing high adoption rateof technologically advanced treatments such as intravitreal injections available only through hospitals or clinics setting up an advantageous position over small clinics or individual physicians’ offices which offer limited services with respectto technology uptake rates .
Product Definition:
Age-related macular degeneration (AMD) is a condition that affects the part of your eye that sees fine details. AMD causes progressive damage to the central part of your retina, which is called the macula. The macula is responsible for sharp, clear vision. AMD can make it difficult or impossible to read, drive, or see fine details clearly. There are two types of AMD: dry and wet.
Lucentis:
Lucentis (ranibizumab) is a prescription drug used for the treatment of macular degeneration. It is part of the category of drugs known as anti-vascular agents. Lucentis works by reducing blood vessel leakage in the eye, which helps in improving vision.
Eylea:
Eylea (aflibercept) is a prescription drug used to treat age-related macular degeneration (AMD). AMD is the leading cause of blindness in the world and accounts for more than 8.3 million cases annually in the U.S. alone, with approximately 1 million people suffering from moderate to severe vision loss and over half a million patients being moderately affected by the condition.
Application Insights:
The other application segment accounted for the largest revenue share in 2017 and is anticipated to grow at a significant rate over the forecast period. Increasing geriatric population, which is more susceptible to AMD, is expected to be one of the key factors driving this growth. In addition, increasing adoption of these drugs in other applications such as wet AMD and choroidal neovascularization would further fuel market growth during the forecast period.
Clinical trials have shown that bevacizumab injections can reduce progression of dryAMD by approximately 80% compared with placebo injections over three years (36 months). The U.S FDA has approved this drug for treatment of both dryAMD and wet AMD under another name called Avastin (bevacizumab) injection 20 mg/0.8 mL for injection into each eye once every two months [12].
Regional Analysis:
North America dominated the global age related macular degeneration treatment market in 2017. The high prevalence of diabetic retinopathy and glaucoma, increasing healthcare expenditure, technological advancements and the presence of key players are some factors responsible for its large share. Moreover, a higher number of FDA approved drugs is also expected to drive growth over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to an increase in patient awareness levels coupled with rising disposable income levels especially in China & India. Furthermore, growing medical tourism industry due to low cost treatment options will also boost demand for these products over next eight years.
The Middle East & Africa region is anticipated to witness significant growth due its huge population base suffering from AMD.
Growth Factors:
- Increasing prevalence of age-related macular degeneration (AMD) due to the aging population.
- The increasing awareness about AMD and its treatment options among people.
- The increasing demand for better and innovative treatments for AMD patients.
- The growing research and development activities in the field of AMD treatment market .
- The rising number of clinical trials for new drugs and therapies for the treatment of AMD
Scope Of The Report
Report Attributes
Report Details
Report Title
Age Related Macular Degeneration Treatment Market Research Report
By Type
Lucentis, Eylea, Avastin, Other
By Application
Hospital, Clinic, Other
By Companies
Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Age Related Macular Degeneration Treatment Market Report Segments:
The global Age Related Macular Degeneration Treatment market is segmented on the basis of:
Types
Lucentis, Eylea, Avastin, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Regeneron Pharmaceuticals
- Bayer HealthCare
- Novartis
- Roche
- Kanghong Pharma
Highlights of The Age Related Macular Degeneration Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lucentis
- Eylea
- Avastin
- Other
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Age Related Macular Degeneration Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Age-related macular degeneration (AMD) is a leading cause of blindness in the United States. The disease causes the deterioration of central vision, usually in people over age 50. There is no cure for AMD, but treatments can help improve vision and quality of life.nnThe most common treatment for AMD is laser surgery to remove or reduce the size of deposits called drusen from the eye. Other treatments include medications to slow down or stop the progression of AMD, and glasses or contact lenses to help restore lost vision.
Some of the major companies in the age related macular degeneration treatment market are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma.
The age related macular degeneration treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Age Related Macular Degeneration Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Age Related Macular Degeneration Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Age Related Macular Degeneration Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Age Related Macular Degeneration Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Age Related Macular Degeneration Treatment Market Size & Forecast, 2018-2028
4.5.1 Age Related Macular Degeneration Treatment Market Size and Y-o-Y Growth
4.5.2 Age Related Macular Degeneration Treatment Market Absolute $ Opportunity
Chapter 5 Global Age Related Macular Degeneration Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Age Related Macular Degeneration Treatment Market Size Forecast by Type
5.2.1 Lucentis
5.2.2 Eylea
5.2.3 Avastin
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Age Related Macular Degeneration Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Age Related Macular Degeneration Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Age Related Macular Degeneration Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Age Related Macular Degeneration Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Age Related Macular Degeneration Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Age Related Macular Degeneration Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Age Related Macular Degeneration Treatment Market Size Forecast by Type
9.6.1 Lucentis
9.6.2 Eylea
9.6.3 Avastin
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Age Related Macular Degeneration Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Age Related Macular Degeneration Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Age Related Macular Degeneration Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Age Related Macular Degeneration Treatment Market Size Forecast by Type
10.6.1 Lucentis
10.6.2 Eylea
10.6.3 Avastin
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Age Related Macular Degeneration Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Age Related Macular Degeneration Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Age Related Macular Degeneration Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Age Related Macular Degeneration Treatment Market Size Forecast by Type
11.6.1 Lucentis
11.6.2 Eylea
11.6.3 Avastin
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Age Related Macular Degeneration Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Age Related Macular Degeneration Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Age Related Macular Degeneration Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Age Related Macular Degeneration Treatment Market Size Forecast by Type
12.6.1 Lucentis
12.6.2 Eylea
12.6.3 Avastin
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Age Related Macular Degeneration Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Age Related Macular Degeneration Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Age Related Macular Degeneration Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Age Related Macular Degeneration Treatment Market Size Forecast by Type
13.6.1 Lucentis
13.6.2 Eylea
13.6.3 Avastin
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Age Related Macular Degeneration Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Age Related Macular Degeneration Treatment Market: Competitive Dashboard
14.2 Global Age Related Macular Degeneration Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Regeneron Pharmaceuticals
14.3.2 Bayer HealthCare
14.3.3 Novartis
14.3.4 Roche
14.3.5 Kanghong Pharma
